Day: October 6, 2025

Ra’anana, Israel, Oct. 06, 2025 (GLOBE NEWSWIRE) — Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company developing intranasal products based on its proprietary Capture & Contain (C&C) platform, today announced encouraging results from a recent pre-clinical study evaluating the allergen-blocking performance of its PL-14 Allergy Blocker formulation. The study was designed to simulate allergen exposure conditions and assess the ability of PL-14 to prevent allergen penetration through a hydrogel barrier. In the pre-clinical study, Der p 1 allergen, a major house dust mite allergen, was applied atop the PL-14 formulation. Samples were collected beneath the formulation at multiple time points to measure the quantity and pace of allergen penetration. The results demonstrated that PL-14 effectively...

Improvement observed in MDS-UPDRS scores in first 9 participants enrolled; 90-day follow-up continuing in remaining participants Plasma exposures in patients within projected therapeutic range and comparable to exposures observed in Phase 1 healthy volunteer study GT-02287 was generally well-tolerated with no treatment emergent serious adverse events (TESAEs); no changes recommended from two independent DMC reviews Gain to host GT-02287 KOL event on October 14th at 4 p.m. EST BETHESDA, Md., Oct. 06, 2025 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today presented a poster at the International Congress of Parkinson’s Disease and Movement Disorders® summarizing...

HIGHLIGHTS2,279 m of infill drilling completed on 10-m drill spacing in 24 drill holes from August 2025 representing ~17.5% of the total planned 13,000-m infill program Highlight intercepts include: 45.24 g/t Au over 3.0 m, including 233.92 g/t Au over 0.5 m, 41.17 g/t Au over 2.1 m, and 16.36 g/t Au over 4.6 m Initial results show good continuity consistent with modelled vein zones and planned stopes, including high-grade intercepts within and adjacent to modelled reserve stopes, reinforcing the potential for delineating new zones and expanding existing ones Systematic underground infill drilling is designed to derisk resource modelling, mine planning and optimize production stope designMONTREAL, Oct. 06, 2025 (GLOBE NEWSWIRE) — Osisko Development Corp. (NYSE: ODV, TSXV: ODV) (“Osisko Development” or the “Company“)...

Company invests in DeSci blockchain innovation and purchases native coin of ResearchHub, a decentralized science platform co-founded by Coinbase CEO, Brian Armstrong SARASOTA, FL, Oct. 06, 2025 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced its initial purchase of ResearchCoin (RSC) as part of its expanded digital assets treasury strategy designed to capture long-term value from emerging multi-chain opportunities. RSC is the native token of ResearchHub, a decentralized platform designed to advance scientific collaboration and discovery. ResearchHub was co-founded in 2019 by Coinbase CEO, Brian Armstrong. “By securing a position in RSC, we are participating in the growing decentralized science...

MaxCyte’s Flow Electroporation® Technology will support efficient gene delivery to advance Moonlight Bio’s engineered T cell therapies ROCKVILLE, Md., Oct. 06, 2025 (GLOBE NEWSWIRE) — MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics, today announced the signing of a Strategic Platform License (SPL) agreement with Moonlight Bio, a preclinical-stage biotechnology company based in Seattle, Washington. Moonlight Bio will deploy MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support the scalable development and manufacturing of its T cell therapy pipeline. “We’re proud to partner with Moonlight Bio as they advance their gene-edited cell therapies through...

SANTA ANA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) — NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that Paul Y. Song, M.D., Chairman and Chief Executive Officer of NKGen, will present at the XXVII World Congress of Neurology (“WCN 2025”) taking place in Seoul, South Korea, October 12-15, 2025. WCN 2025 is a premier global forum that brings together leading neurologists, researchers, and healthcare professionals to exchange knowledge, foster collaboration, and explore breakthrough innovations in neurological science. At this year’s congress in Seoul, South Korea, NKGen Biotech will present the scientific rationale and latest clinical...

WILMINGTON, Del., Oct. 06, 2025 (GLOBE NEWSWIRE) — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, or the “Company”), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., (“HOPE,” or the “Company”), an interventional psychiatry network wholly owned by NRx Pharmaceuticals, will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference on October 8, 2025 at 9:30 a.m. Eastern Time. Jonathan Javitt, M.D., M.P.H., Founder, Chairman, and Chief Executive Officer of NRx Pharmaceuticals will provide a corporate update, including a discussion of the Company’s plan to launch a low-dose D-Cycloserine (DCS) product based on recent medical evidence that low-dose DCS more than doubles the clinical effectiveness of Transcranial Magnetic Stimulation...

Figure 1 – White Gold DistrictFigure 1 – White Gold DistrictFigure 2 – Updated Mineralization Model ComparisonFigure 2 – Updated Mineralization Model ComparisonFigure 3 – Updated Resource Block ModelFigure 3 – Updated Resource Block ModelFigure 4 – White Gold Property Expansion OpportunitiesFigure 4 – White Gold Property Expansion OpportunitiesFigure 5 – 2025 Golden Saddle Drilling OverviewFigure 5 – 2025 Golden Saddle Drilling OverviewFigure 6 – Golden Saddle Main Zone Long SectionFigure 6 – Golden Saddle Main Zone Long SectionTORONTO, Oct. 06, 2025 (GLOBE NEWSWIRE) — White Gold Corp. (TSX.V: WGO, OTCQX: WHGOF, FRA: 29W) (the “Company”) is pleased to announce the filing of an updated National Instrument 43-101 (“NI 43-101”) technical report for its White Gold Project, located...